As of 1 June, COVID-19 test sales were €45M (£40M).
The company has received orders for, or been contracted to deliver, a further €90M (£80M) of its COVID-19 test.
During H2, additional COVID-19 related sales are
expected from Company’s new products, Exsig Direct and Exsig Mag, and
from mobile testing solution. Both Exsig extraction reagents will launch
during June and the mobile COVID-19 system will launch in July.
Also, the company has earned a contract for the
supply of 1.5M tests in Zimbabwe. The initial purchase order for the
first 500,000 tests has been received and will be shipped immediately.
Haute Autorité de Santé, an advisor the French
government on medical reimbursement, did not approved company’s COVID-19
test for reimbursement in France.
Novacyt has secured registrations and regulatory
approvals in the following new markets for its COVID-19 test: Panama,
Ecuador, Columbia, Peru, Paraguay and the UAE.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.